Krajowa Konferencja Zastosowań Matematyki w Biologii i Medycynie

Jugowice, 11th–15th September 2017

TWO MODELS OF DRUG RESISTANCE FOR LOW GRADE GLIOMAS: COMPARISON OF THE MODELS DYNAMICS

Marek Bodnar[1], **Urszula Foryś**[2]

[1,2]Faculty of Mathematics, Informatics and Mechanics, University of Warsaw,
ul. Banacha 2, 02-097 Warsaw,
[1]mbodnar@mimuw.edu.pl, [2]urszula@mimuw.edu.pl

ABSTRACT

We present simple mathematical models of two mechanism of acquiring a drug resistance. Acquired drug resistance syndrom (ADR) is one of the most important features associated with tumour treatment and is therefore a topic of intensive studies. Basing on the simple mathematical approach we conclude that for constant continuous treatment once resistant cells appear, sensitive cells are eliminated after long time, independently of the mechanism of acquiring the resistance. We discuss these mechanisms on the example of gliomas.

ACKNOWLEDGEMENTS

This work was supported by National Science Centre, Poland, under the project No. 2015/19/B/ST1/01163.

REFERENCES

[1] M. Bodnar and U. Foryś: *Three types of simple DDE'S describing tumor growth*, J. Biol. Syst. **15** (2007) (doi:10.1142/S0218339007002313), 453–471.

[2] S. Kesari, D. Schiff, J. Drappatz, D. LaFrankie, L. Doherty, E.A. Macklin, A. Muzikansky, S. Santagata, K.L. Ligon, A.D. Norden, A. Ciampa, J. Bradshaw, B. Levy, G. Radakovic, N. Ramakrishna, P.M. Black, and P.Y. Wen: *Phase II study of protracted daily temozolomide for low-grade gliomas in adults*, Clinical Cancer Research **15** (2009) (doi: 10.1158/1078-0432), 330–7.

[3] D.N. Louis, A. Perry, G. Reifenberger, A. von Deimling, D. Figarella-Branger, Cavenee W.K., H. Ohgaki, O.D. Wiestler, P. Kleihues, and D.W. Ellison: *The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary*, Acta Neuropathol. **131** (2016) (10.1007/s00401-016-1545-1), 803–820.

[4] E. Ollier, P. Mazzocco, D. Ricard, G. Kaloshi, A. Idbaih, A. Alentorn, D. Psimaras, J. Honnorat, J. Delattre, E. Grenier, F. Ducray, and A. Samson: *Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model*, Fundamental & Clinical Pharmacology (2017) (doi:10.1111/fcp.12259).

[5] V.M. Perez-García, M. Bogdańska, A. Martínez-González, J. Belmonte-Beitia, P. Schucht, and L.A. Pérez-Romasanta: *Delay effects in the response of low-grade gliomas to radiotherapy: a mathematical model and its therapeutical implications*, Mathematical Medicine and Biology: A Journal of the IMA **32** (2015) (doi:10.1093/imammb/dqu009), 307–329.

[6] N. Pouratian, J. Gasco, J.H. Sherman, M.E. Shaffrey, and D. Schiff: *Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas*, Journal of Neurooncology **82** (2007), 281–288.